Buy Rating Affirmed for Avenue Therapeutics Amid Strong Prospects for IV Tramadol and Strategic Growth Potential
Analysts Conflicted on These Healthcare Names: Avenue Therapeutics (ATXI) and Inovio Pharmaceuticals (INO)
Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75
Avenue Therapeutics Analyst Ratings
Aegis Capital Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $32
No Data